Breast Cancer "Tailored Follow-up" in Italian Oncology Units: A Web-Based Survey

被引:7
作者
Natoli, Clara [1 ]
Brocco, Davide [1 ]
Sperduti, Isabella [2 ]
Nuzzo, Antonio [3 ]
Tinari, Nicola [1 ]
De Tursi, Michele [1 ]
Grassadonia, Antonino [1 ]
Mazzilli, Lorenzo [4 ]
Iacobelli, Stefano [1 ]
Gamucci, Teresa [5 ]
Vici, Patrizia [6 ]
机构
[1] Univ G Dannunzio, Dept Expt & Clin Sci, Chieti, Italy
[2] Regina Elena Inst Canc Res, Unit Biostat, Rome, Italy
[3] Floraspe Renzetti Hosp, Dept Oncol, Lanciano, Italy
[4] SS Annunziata Hosp, Clin Governance Unit, Chieti, Italy
[5] SS Trinita Hosp, Dept Oncol, Sora, Italy
[6] Regina Elena Inst Canc Res, Div Med Oncol B, Rome, Italy
来源
PLOS ONE | 2014年 / 9卷 / 04期
关键词
AMERICAN-SOCIETY; ADJUVANT THERAPY; CARE; GUIDELINES; WOMEN; SURVEILLANCE; RECURRENCE; DISEASE; UPDATE; EXPERIENCE;
D O I
10.1371/journal.pone.0094063
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose: Breast cancer follow-up procedures after primary treatment are still a controversial issue. Aim of this study was to investigate, through a web-based survey, surveillance methodologies selected by Italian oncologists in everyday clinical practice. Methods: Referents of Italian medical oncology units were invited to participate to the study via e-mail through the SurveyMonkey website. Participants were asked how, in their institution, exams of disease staging and follow-up are planned in asymptomatic women and if surveillance continues beyond the 5th year. Results: Between February and May 2013, 125 out of 233 (53.6%) invited referents of Italian medical oncology units agreed to participate in the survey. Ninety-seven (77.6%) referents state that modalities of breast cancer follow-up are planned according to the risk of disease progression at diagnosis and only 12 (9.6%) oncology units apply the minimal follow-up procedures according to international guidelines. Minimal follow-up is never applied in high risk asymptomatic women. Ninety-eight (78.4%) oncology units continue follow-up in all patients beyond 5 years. Conclusions: Our survey shows that 90.4% of participating Italian oncology units declare they do not apply the minimal breast cancer follow-up procedures after primary treatment in asymptomatic women, as suggested by national and international guidelines. Interestingly, about 80.0% of interviewed referents performs the so called '' tailored follow-up '', high intensity for high risk, low intensity for low risk patients. There is an urgent need of randomized clinical trials able to determine the effectiveness of risk-based follow-up modalities, their ideal frequency and persistence in time.
引用
收藏
页数:7
相关论文
共 52 条
  • [1] [Anonymous], Early and locally advanced breast cancer: diagnosis and management NICE guideline
  • [2] Associazione Italiana Oncologia Medica, LIN GUID TUM MAMM
  • [3] Long-term toxic effects of adjuvant chemotherapy in breast cancer
    Azim, H. A., Jr.
    de Azambuja, E.
    Colozza, M.
    Bines, J.
    Piccart, M. J.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (09) : 1939 - 1947
  • [4] Barni S, 2011, TUMORI J, V97, P559, DOI 10.1700/989.10711
  • [5] Bell RJ, 2013, INTERN MED J
  • [6] Use of imaging in surveillance of women with early stage breast cancer
    Bell, Robin J.
    Schwarz, Max
    Fradkin, Pamela
    Davis, Susan R.
    [J]. ANZ JOURNAL OF SURGERY, 2013, 83 (03) : 129 - 134
  • [7] Survivorship care after breast cancer: Follow-up practices of Australian health professionals and attitudes to a survivorship care plan
    Brennan, Meagan E.
    Butow, Phyllis
    Spillane, Andrew J.
    Boyle, Frances M.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2010, 6 (02) : 116 - 125
  • [8] Prognostic impact of the early detection of metachronous contralateral breast cancer
    Ciatto, S
    Guido, M
    Marco, Z
    [J]. EUROPEAN JOURNAL OF CANCER, 2004, 40 (10) : 1496 - 1501
  • [9] Follow-up care of patients treated for breast cancer: a structured review
    Collins, RF
    Bekker, HL
    Dodwell, DJ
    [J]. CANCER TREATMENT REVIEWS, 2004, 30 (01) : 19 - 35
  • [10] Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
    Davies, Christina
    Pan, Hongchao
    Godwin, Jon
    Gray, Richard
    Arriagada, Rodrigo
    Raina, Vinod
    Abraham, Mirta
    Medeiros Alencar, Victor Hugo
    Badran, Atef
    Bonfill, Xavier
    Bradbury, Joan
    Clarke, Michael
    Collins, Rory
    Davis, Susan R.
    Delmestri, Antonella
    Forbes, John F.
    Haddad, Peiman
    Hou, Ming-Feng
    Inbar, Moshe
    Khaled, Hussein
    Kielanowska, Joanna
    Kwan, Wing-Hong
    Mathew, Beela S.
    Mittra, Indraneel
    Mueller, Bettina
    Nicolucci, Antonio
    Peralta, Octavio
    Pernas, Fany
    Petruzelka, Lubos
    Pienkowski, Tadeusz
    Radhika, Ramachandran
    Rajan, Balakrishnan
    Rubach, Maryna T.
    Tort, Sera
    Urrutia, Gerard
    Valentini, Miriam
    Wang, Yaochen
    Peto, Richard
    [J]. LANCET, 2013, 381 (9869) : 805 - 816